Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ERIC 2018 | Novel ventoclax combinations for CLL

Eva Kimby • 25 Oct 2018
ERIC 2018
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Obinutuzumab Venetoclax

The future of chronic lymphocytic leukemia (CLL) treatment is bright and looking towards novel combinations. Here, Eva Kimby, MD, PhD, of the Karolinska University Hospital, Solna, Sweden, gives us her thoughts on promising novel therapies, including venetoclax combinations. This interview took place at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.

More from Eva Kimby

Great debates in WM: standard front-line treatment, continuous versus fixed-duration BTKis, & more
3:05
Great debates in WM: standard front-line treatment, continuous versus fixed-duration BTKis, & more
Eva Kimby • 19 Oct 2024
A perspective on MRD in CLL: treatment efficacy, early relapse detection & more
1:25
A perspective on MRD in CLL: treatment efficacy, early relapse detection & more
Eva Kimby • 25 Oct 2018
A perspective on the current landscape of CLL treatment
2:11
A perspective on the current landscape of CLL treatment
Eva Kimby • 25 Oct 2018

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Eva Kimby • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Eva Kimby • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Eva Kimby • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Eva Kimby • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals